Maxim Group analyst Naz Rahman maintained a Buy rating on Virpax Pharmaceuticals (VRPX – Research Report) yesterday and set a price target of $4.00. The company’s shares closed yesterday at $0.80.
Rahman covers the Healthcare sector, focusing on stocks such as Agile Therapeutics, 9 Meters Biopharma, and Processa Pharmaceuticals. According to TipRanks, Rahman has an average return of -34.8% and a 20.69% success rate on recommended stocks.
Virpax Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $4.06 and a one-year low of $0.68. Currently, Virpax Pharmaceuticals has an average volume of 35.42K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Virpax Pharmaceuticals Inc is a preclinical-stage pharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management.
Read More on VRPX:
